BFM
NEUP

Boothbay Fund Management’s Neuphoria Therapeutics NEUP Stock Holding History

Boothbay Fund Management’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.2K Hold
14,000
– – ﹤0.01% 2083
2026
Q1 		$57K Hold
14,000
– – ﹤0.01% 1913
2025
Q4 		$54.3K Buy
+14,000
New +$99.5K ﹤0.01% 1814

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Boothbay Fund Management's NEUP Position: Q2 2026 in Review

Boothbay Fund Management held its Neuphoria Therapeutics (NEUP) position steady in Q2 2026 at 14,000 shares worth $61.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2083.

Boothbay Fund Management first reported a position in NEUP in Q4 2025 and has held it in 3 quarters since. 22 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • Boothbay Fund Management held 14,000 shares of Neuphoria Therapeutics worth $61.2K as of Q2 2026.
  • Boothbay Fund Management left its Neuphoria Therapeutics share count unchanged in Q2 2026.
  • Neuphoria Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2083 holding.
  • Boothbay Fund Management first reported a position in Neuphoria Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 22 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.